SG11201707471RA - Tricyclic heterocyclic compounds useful as inhibitors of tnf - Google Patents
Tricyclic heterocyclic compounds useful as inhibitors of tnfInfo
- Publication number
- SG11201707471RA SG11201707471RA SG11201707471RA SG11201707471RA SG11201707471RA SG 11201707471R A SG11201707471R A SG 11201707471RA SG 11201707471R A SG11201707471R A SG 11201707471RA SG 11201707471R A SG11201707471R A SG 11201707471RA SG 11201707471R A SG11201707471R A SG 11201707471RA
- Authority
- SG
- Singapore
- Prior art keywords
- tnf
- inhibitors
- heterocyclic compounds
- compounds useful
- tricyclic heterocyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134779P | 2015-03-18 | 2015-03-18 | |
| PCT/US2016/022738 WO2016149437A1 (en) | 2015-03-18 | 2016-03-17 | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707471RA true SG11201707471RA (en) | 2017-10-30 |
Family
ID=55640933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707471RA SG11201707471RA (en) | 2015-03-18 | 2016-03-17 | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10308652B2 (enExample) |
| EP (1) | EP3271361B1 (enExample) |
| JP (1) | JP6793658B2 (enExample) |
| KR (1) | KR102630010B1 (enExample) |
| CN (1) | CN107635992B (enExample) |
| AU (1) | AU2016233289A1 (enExample) |
| BR (1) | BR112017019731A2 (enExample) |
| CA (1) | CA2982446A1 (enExample) |
| EA (1) | EA032314B1 (enExample) |
| ES (1) | ES2797685T3 (enExample) |
| IL (1) | IL254520A0 (enExample) |
| MX (1) | MX2017011433A (enExample) |
| SG (1) | SG11201707471RA (enExample) |
| WO (1) | WO2016149437A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201707469WA (en) | 2015-03-18 | 2017-10-30 | Bristol Myers Squibb Co | Substituted tricyclic heterocyclic compounds |
| ES2803650T3 (es) | 2015-03-18 | 2021-01-28 | Bristol Myers Squibb Co | Compuestos heterocíclicos útiles como inhibidores de TNF |
| TW201706258A (zh) | 2015-04-17 | 2017-02-16 | 艾伯維有限公司 | 作為ｔｎｆ信號傳遞調節劑之吲唑酮 |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| TW201702247A (zh) | 2015-04-17 | 2017-01-16 | 艾伯維有限公司 | 作為ｔｎｆ信號傳遞調節劑之吲唑酮 |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| AU2016301215A1 (en) | 2015-08-03 | 2018-03-22 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of TNF alpha |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| EP3596078B1 (en) | 2017-03-15 | 2023-04-12 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391806A (en) * | 1982-07-12 | 1983-07-05 | The Dow Chemical Company | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators |
| JP2001513084A (ja) | 1997-02-25 | 2001-08-28 | ザ ガバメント オブ ザ ユナイテッド ステーツ オブ アメリカ，レプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ | 逆転写酵素の非ヌクレオシド阻害剤としての置換ベンズイミダゾール |
| EP1224185B1 (en) * | 1999-10-27 | 2005-11-30 | Novartis AG | Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use |
| JPWO2003064422A1 (ja) | 2002-01-31 | 2005-05-26 | 第一製薬株式会社 | イミダゾ［１，２−ａ］ピリジン誘導体 |
| AU2003298839A1 (en) | 2002-12-03 | 2004-06-23 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| US20110009403A1 (en) | 2007-10-05 | 2011-01-13 | S*Bio Pte Ltd. | 2-morpholinylpurines as inhibitors of pi3k |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| CN104428293B (zh) | 2012-06-11 | 2018-06-08 | Ucb生物制药私人有限公司 | 调节TNFα的苯并咪唑类 |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| BR112015000675B1 (pt) | 2012-07-13 | 2022-07-12 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores da atividade de tnf |
| KR20150081354A (ko) * | 2012-11-07 | 2015-07-13 | 에프. 호프만-라 로슈 아게 | 트라이아졸로 화합물 |
| ES2529865B8 (es) * | 2013-07-25 | 2016-01-22 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) | USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS |
| CN105814022B (zh) | 2013-12-09 | 2018-09-28 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合的二环杂芳族衍生物 |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| JP6469692B2 (ja) | 2013-12-09 | 2019-02-13 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体 |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| EA201790779A1 (ru) | 2014-10-06 | 2017-09-29 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений |
| ES2803650T3 (es) | 2015-03-18 | 2021-01-28 | Bristol Myers Squibb Co | Compuestos heterocíclicos útiles como inhibidores de TNF |
| SG11201707469WA (en) | 2015-03-18 | 2017-10-30 | Bristol Myers Squibb Co | Substituted tricyclic heterocyclic compounds |
| AR104291A1 (es) * | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| EP3292127A1 (en) * | 2015-05-04 | 2018-03-14 | Actelion Pharmaceuticals Ltd | Tricyclic piperidine compounds |
-
2016
- 2016-03-17 US US15/558,708 patent/US10308652B2/en active Active
- 2016-03-17 CA CA2982446A patent/CA2982446A1/en not_active Abandoned
- 2016-03-17 SG SG11201707471RA patent/SG11201707471RA/en unknown
- 2016-03-17 EP EP16712646.5A patent/EP3271361B1/en active Active
- 2016-03-17 BR BR112017019731-6A patent/BR112017019731A2/pt not_active Application Discontinuation
- 2016-03-17 JP JP2017549093A patent/JP6793658B2/ja active Active
- 2016-03-17 WO PCT/US2016/022738 patent/WO2016149437A1/en not_active Ceased
- 2016-03-17 ES ES16712646T patent/ES2797685T3/es active Active
- 2016-03-17 KR KR1020177029450A patent/KR102630010B1/ko active Active
- 2016-03-17 AU AU2016233289A patent/AU2016233289A1/en not_active Abandoned
- 2016-03-17 EA EA201792025A patent/EA032314B1/ru not_active IP Right Cessation
- 2016-03-17 CN CN201680025154.3A patent/CN107635992B/zh active Active
- 2016-03-17 MX MX2017011433A patent/MX2017011433A/es unknown
-
2017
- 2017-09-15 IL IL254520A patent/IL254520A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3271361B1 (en) | 2020-04-22 |
| EP3271361A1 (en) | 2018-01-24 |
| AU2016233289A1 (en) | 2017-11-09 |
| US10308652B2 (en) | 2019-06-04 |
| EA201792025A1 (ru) | 2018-01-31 |
| EA032314B1 (ru) | 2019-05-31 |
| ES2797685T3 (es) | 2020-12-03 |
| CN107635992B (zh) | 2020-05-22 |
| KR20170129811A (ko) | 2017-11-27 |
| US20180111937A1 (en) | 2018-04-26 |
| MX2017011433A (es) | 2017-11-10 |
| CA2982446A1 (en) | 2016-09-22 |
| JP6793658B2 (ja) | 2020-12-02 |
| CN107635992A (zh) | 2018-01-26 |
| BR112017019731A2 (pt) | 2018-05-22 |
| WO2016149437A1 (en) | 2016-09-22 |
| JP2018508554A (ja) | 2018-03-29 |
| KR102630010B1 (ko) | 2024-01-25 |
| IL254520A0 (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03740B (me) | Jedinjenja indol karboksamida korisna kao inhibitori kinaze | |
| ZA201800716B (en) | Heterocyclic compounds useful as modulators of tnf alpha | |
| ZA201706710B (en) | Heterocyclic compounds as lsd1 inhibitors | |
| HUE059324T2 (hu) | Heterociklusos vegyületek, mint PI3K-gamma inhibitorok | |
| IL255817B (en) | Synthesis of heterocyclic compounds | |
| ZA201700304B (en) | Spirocycloheptanes as inhibitors of rock | |
| IL254520A0 (en) | Heterocyclic tricyclic compounds for use as tnf inhibitors | |
| IL279949A (en) | Heterocyclic MCT4 inhibitors | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| ZA201605586B (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| IL254430A0 (en) | Heterocyclic compounds are useful as TNF inhibitors | |
| IL254424A0 (en) | Disubstituted heterocyclic tricyclic compounds | |
| IL257501B (en) | Compounds containing heterocyclic tricyclic compounds |